Immunotherapy with Autologous Tregs in T1DM

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

Ex vivo Expanded Human Autologous Regulatory T Cells

Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

OTHER

Routine Care

Routine care is provided to all participants according to clinical guidelines for T1DM.

Trial Locations (1)

Unknown

RECRUITING

The Department of Endocrinology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
collaborator

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

OTHER

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER